Open orphan WKN: A1KAME ISIN: GB00B9275X97 Kürzel: CRO Forum: Aktien User: Heromero

Morgens runter, abends hoch 😅🙈 sind news in Aussicht? Das sie angefangen haben gesunde Patienten mit COVID zu infezieren ist ja nun auch schon bisschen her

Der Kurs an der Nasdaq hat sich heute verändert! Anscheinend kann die Aktie nun auch dort gehandelt werden!

Dümpelt vor sich hin 😁

Wir sind hier scheinbar zwischen 0,30 und0,36 gefangen

???

Wenn ihr den Chat davor lest werdet ihr verstehen, dass hier viel erwartet wird und dass ihr es richtig gemacht habt mit der Investition .

Bin investiert

👍 Allerdings ohne echten Plan, wo die Reise hingehen könnte

✌️

Bin hier auch mit ner kleinen Position dabei

Ist hier wer investiert? Ich bin mal mit ner kleinen Position dabei. Ist denke ich auch nach Covid noch eine gute Anlage.

https://hvivo.com/wp-content/uploads/2021/03/2021-JCS-1-February-42-45.pdf

und es wir auch auf dieses pdf verwiesen

@tanja danke!!!!

@criscros: das steht im link...

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations. Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies. Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases. Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.